display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
non squamous - mNSCLC - L1 - Wild Type (WT)squamous - mNSCLC - L1 - all population
pembrolizumab plus SoC KEYNOTE-189 KEYNOTE-407

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons